Although the intestinal epithelium provides a barrier against foreign materials and microorganisms present in the intestinal lumen, numerous pathogens enter the body through this cellular layer. Protection of the vast mucosal surface of the intestine depends in part on cells of the local mucosal immune system that sample lumenal antigens and generate an immune response including antigen-sensitized T lymphocytes and B lymphocytes that produce polymeric immunoglobulin A (IgA) antibodies. Secretory IgA (sIgA) antibodies are thought to provide mucosal defense by immune exclusion; this refers to their ability to prevent contact of pathogens with epithelial surfaces through agglutination in the intestinal lumen, entrapment of immune complexes in mucus, and clearance by peristalsis (1, 6, 12, 15) . The relative importance of sIgA antibodies in protection against infection with Salmonella sp. has not been clearly established (7) . Typhoid patients and humans given live oral typhoid vaccines have circulating IgG, IgM, and IgA antibodies and cellular immunity as well as sIgA antibodies directed against Salmonella typhi (3, 5, 11, 14, 20) . The protective capacity of specific IgA antibodies has not previously been tested, in part because of the difficulties in obtaining well-characterized sIgA antibodies in sufficient amounts and in delivering exogenous IgA antibodies into normal mucosal secretions.
We recently developed methods for efficient production of IgA hybridomas from Peyer's patch cells (25) and for delivery of monoclonal IgA antibodies into intestinal secretions via the normal transepithelial transport mechanism (26) . With dose of virulent vibrios (26) . V. cholerae, however, does not penetrate the intestinal mucosa or generate a systemic infection. Thus, it is not known whether sIgA alone can prevent entry of invasive bacteria into the mucosa, infection of mucosal cells, and systemic spread.
To address this issue, we have studied the invasive pathogen Salmonella typhimunum in a mouse model. S. typhimurium, a gram-negative bacterium, invades the intestinal epithelium, infects cells of the reticulo-endothelial system, and results in infection of liver and spleen (10) . Systemic dissemination produces a lethal disease in mice that is similar to enteric fever in humans caused by S. typhi (4) . In mice, early entry of S. typhimunum is via transepithelial transport by M cells of Peyer's patches (10, 13) . Later, absorptive enterocytes can be invaded and damaged, providing an additional portal of entry (23) . Infection of cells in Peyer's patch mucosa is followed by bacteremia and systemic disease that can be mimicked by intraperitoneal (i.p.) injection of organisms (4) . S. typhimurium is also a human pathogen, causing acute gastroenteritis (9) . It is therefore important to determine the role of sIgA antibodies in providing mucosal protection against this organism. Furthermore, identification of Salmonella epitopes that are immunogenic and protective in the mucosal immune system is relevant to design of both active and passive immunization protocols. In this report, we show that a single monoclonal sIgA, secreted into the lumen of the mouse intestine by the normal epithelial transport mechanism, is sufficient to confer protection against an oral challenge of S. typhimunum.
MATERUILS AND METHODS
Bacterial strains. All bacterial strains used in this study are derivatives of S. typhimunum ATCC 14028 (16) . Immunization was repeated at day 10. On day 14, mice were sacrificed by cervical dislocation and the Peyer's patches (7 to 10 per mouse) were excised. Peyer's patch lymphocytes were isolated, pooled, washed in tissue culture medium, and fused with P3X63/Ag8U.1 mouse myeloma cells as previously described (25) . Fusion products were plated in 96-well plates with feeder layers of thymocytes isolated from DBA/2 mice. Hybridoma cell cultures were grown in RPMI tissue culture medium (Sigma Chemical Co., St Louis, Mo.) supplemented with 10% fetal bovine serum, 2 mM glutamine (GIBCO Laboratories, Grand Island, N.Y.), 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; Sigma), and 1 mM sodium pyruvate (GIBCO).
Culture supernatants were screened for the production of anti-S. typhimunum immunoglobulin by enzyme-linked immunosorbent assay (ELISA) with S. typhimunum 14028 whole-cell lysate as the immobilized antigen and rabbit anti-mouse IgG, IgA, and IgM antibodies coupled to peroxidase (Zymed Laboratories, South San Francisco, Calif.) as the secondary antibody. Positive wells were verified and isotyped by using rabbit antibodies directed against mouse IgA, IgG, or IgM (Zymed). The isotype of the monoclonal antibodies was identified by coating ELISA plates with the antibody to be tested at pH 9.6 and performing ELISA assays with anti-heavy chain isotype-specific antisera (Boehringer GmbH, Mannheim, Germany) as the primary antibodies. Specific IgA-producing hybridomas were expanded and frozen. The IgA hybridomas selected for further investigation were cloned three times by limiting dilution on DBA/2 thymocyte feeder layers.
Characterization of anti-S. typhimurium monoclonal antibodies. S. typhimunum lysates were prepared by boiling whole cells in sample buffer, and proteins were separated on 10% polyacrylamide-sodium dodecyl sulfate (SDS) gels and transferred to nitrocellulose. The nitrocellulose blots were blocked in 5% nonfat dry milk in phosphate-buffered saline (PBS) followed by incubation in IgA-producing hybridoma culture supernatant. The blots were then incubated with biotin-linked rabbit anti-mouse IgA (Zymed) as a secondary antibody, with subsequent incubation with streptavidin coupled to peroxidase (Pierce, Rockford, Ill.). To assess the recognition of carbohydrate epitopes by the monoclonal IgA, nitrocellulose strips were incubated in periodic acid (Sigma) at pH 4.5 before application of IgA antibodies, as previously described (27 Complement activation assay. A complement sensitivity assay was performed as previously described (19) . Briefly, bacteria from overnight cultures were washed once, resuspended in PBS at 107 CFU/ml, and aliquoted into glass tubes. Antibody was added to the bacteria at various dilutions in cell culture medium, and then guinea pig complement (Difco Laboratories, Detroit, Mich.) was added to a final concentration of 20%. Negative control tubes in which the antibody was omitted or replaced by unrelated anti-V. cholerae monoclonal IgA were prepared. Rabbit anti-S. typhimurium antiserum (Difco) was used as positive control. All tubes were incubated at 37°C for 15 min, the reactions were stopped by addition of ice-cold LB, and the CFU were determined by plating at increasing dilutions on LB plates. Results were recorded as percent survival in the reaction mixture compared with that in the negative control.
In vivo protection experiments. At day 0, 106 hybridoma cells were subcutaneously injected in the upper backs of 6-to 8-week-old nonimmune BALB/c female mice to generate IgA-secreting hybridoma tumors, as previously described (26) . Prior to injection, the IgA-producing hybridoma cells were grown to 40 to 50% saturation, harvested, and washed twice in sterile PBS. Mice were injected with hybridoma cells producing either anti-S. typhimurium IgA (clone Sal4) or anti-V. cholerae IgA (clone 2D6 [26] ). At day 12, blood was obtained from all mice by tail bleed, and levels in serum of anti-Salmonella sp. or anti-V. cholerae IgA were measured by ELISA analysis as described below. About 70% of these mice showed serum levels of specific IgA detectable at a 1/1,000 dilution, and only these mice were included further in the protocols. At sacrifice, representative mice from this group also showed specific IgA in intestinal secretions diluted in 2 ml during intestinal lavage and further diluted 1:10 for ELISA. At day 13, mice were challenged by intragastric intubation of 105, 106, or 107 MT11O or MT114 S. typhimurium cells in 0.1 M phosphate buffer, pH 8. During the entire experimental period mice were given food and water ad libitum. Five days after challenge, the mice were VOL. 60, 1992 on October 29, 2017 by guest http://iai.asm.org/ Downloaded from sacrificed and their spleens were removed and homogenized between sterilized frosted glass slides in saline. Dilutions of the homogenates were plated on LB plates containing 100 ,ug of streptomycin per ml to determine the number of viable bacterial cells.
Additional groups of tumor-bearing mice (prepared as described above) were challenged by i.p. injection of 20, 200, or 2,000 MT110 or MT114 S. typhimurium cells in saline solution. These mice were sacrificed 3 days postchallenge, and spleens were removed and treated as described above. To determine entry of S. typhimurium into Peyer's patch mucosa, other groups of mice were prepared and perorally challenged as described above but were sacrificed 2 days after challenge. After collection of blood samples, the entire small intestine was removed and all visible Peyer's patches were excised. Whole Peyer's patches, including the entire intestinal wall from lumenal surface to seros', were rinsed in PBS and pooled for each mouse. To eliminate endogenous streptomycin-sensitive lumenal bacteria, intact tissue samples were immersed in RPMI culture medium supplemented with 10% fetal bovine serum and 50 ,ug of streptomycin per ml for 20 min at 4°C followed by 20 min at 23°C and again rinsed twice in cold PBS. To kill any extracellular S. typhimunium remaining associated with the mucosal surface, we adapted methods previously described for cultured epithelial cells (8) . Intact Peyer's patch tissues were incubated in culture medium containing 50 ,ug of gentamicin per ml for 20 min at 23°C and then again rinsed twice in cold PBS. Peyer's patches were then homogenized between groundglass slides in 2 ml of cold PBS, and dilutions were plated as described above for spleens.
ELISA of serum and gut wash samples. After 2 h of clotting at room temperature, blood samples were centrifuged for 3 min at 7,000 x g, and serum was collected. Samples were frozen at -20°C if not used immediately. Gut wash samples were obtained from control mice that were carrying a hybridoma tumor but were not challenged. The small intestine was flushed with 2 ml of PBS containing 1 mM phenylmethylsulfonyl fluoride (Boehringer), and the flushed lumenal material was collected distally and centrifuged at 1,000 x g for 5 min to remove debris. The supernatant was centrifuged at 7,000 x g for 10 min to remove cells and bacteria. Dilutions of serum and gut wash samples in PBS were applied to ELISA plates coated with S. typhimunium wholecell lysate as an immobilized antigen. Rabbit antibodies directed against mouse IgA, coupled to biotin (Zymed), were used as a secondary antibody and were detected with streptavidin-horseradish peroxidase (Pierce). IgA monoclonal antibodies from hybridoma culture supernatant served as a control. RESULTS Production of monoclonal IgA directed against S. typhimurium. As the first step in the production of monoclonal antibodies, we orally immunized BALB/c mice with live S. typhimurium. In order to maximize antigen delivery to the mucosal immune system of mice without causing lethal disease, we used attenuated strains of S. typhimurium containing either a phoP constitutive allele, phoP24, or a phoP null allele, phoP102::TnJOd-Cm (16, 17 (Fig. !A, (12, 25) .
into secretions in vivo, we generated subcutaneous hybridoma tumors in mice and tested serum and intestinal secretions of the mice for anti-S. typhimurium IgA activity by ELISA. Specific anti-Salmonella IgA was present both in serum (at a 1:1,000 dilution) and intestinal washes (at a 1:10 dilution) from all mice bearing Sai4 hybridoma tumors but was undetectable in serum or secretions from mice bearing anti-V. cholerae hybridoma tumors. We previously demonstrated that in mice bearing hybridoma tumors, there is a close correlation between the level of specific IgA in serum with that measured in intestinal secretions (26) . Therefore Sal4 monoclonal IgA prevents systemic infection after oral inoculation of S. typhimurium. To test if a monoclonal IgA is sufficient to confer protection against oral challenge with S. typhimurium, IgA was delivered into mucosal secretions from hybridoma tumors in mice, as previously described (26) . The hybridoma tumors produce specific IgA in the bloodstream, a portion of which is transported into the lumen of the intestine via receptor-mediated transepithelial transport (21, 26) . The tumor-bearing mice were then orally challenged with S. typhimurium. S. typhimurium invades the intestinal mucosa, and after a transient bacteremia, a progressive infection of the reticulo-endothelial system is established (4, 10) . Since a consistent result of this systemic spread is a characteristic infection of the spleen and liver, monitoring of the bacterial CFU in the spleen is a reliable measurement of systemic infection. Injection of less than 10 S. typhimurium cells i.p. bypasses the epithelial barrier and almost invariably results in a lethal systemic infection. Therefore, our criterion for complete protection against infection after oral challenge was sterility of the spleen. not show the progressive decline in general health that resulted from tumor growth, and therefore the progression of infection with S. typhimurium was slower (data not shown).
Twelve days after injection of hybridoma cells, when visible tumors had formed in at least 70% of the mice, blood samples were taken from each mouse and serum levels of anti-S. typhimurium or anti-V. cholerae IgA were determined. Mice that had specific serum IgA detectable at a 1:1,000 dilution were retained in the study. The following day, these mice were orally challenged with various doses of wild-type S. typhimurium MT11O or the Agg4 mutant, MT114. Viable bacterial counts in spleens were determined 5 days postchallenge.
The data depicted in Fig. 2 show that in a typical experiment, all mice bearing Sal4 IgA hybridoma tumors had sterile spleens 5 days after oral challenge with 107 wild-type S. typhimurium cells. In contrast, spleens of mice bearing Sal4 IgA tumors were consistently infected by the Agg4 mutant. Similarly, both of the two control mice carrying hybridomas secreting anti-V. cholerae IgA antibody had infected spleens after oral challenge with wild-type S. typhimurium (data not shown).
In a separate experiment designed to test the capacity of secreted IgA to defend against very high numbers of S. typhimunum cells in the gut, mice bearing Sal4 IgA hybridoma tumors were challenged orally with 109 cells of strain MT110 or MT114. Although the total numbers of bacteria recovered from the spleens were lower in tumor-bearing mice challenged with the wild-type MT110 strain than in those challenged with the Agg4 mutant MT114, all mice challenged with 109 bacteria were consistently infected (data not shown).
Sal4 IgA does not prevent systemic infection after i.p. challenge with S. typhimurium. Having shown that secretion of Sal4 IgA from hybridoma tumors prevented systemic infection after oral challenge with up to 107 S. typhimunum cells, we sought to determine at what stage in the infection pathway the IgA protection occurred. In normal mucosal immunity, blood levels of polymeric IgA are low because most IgA is produced locally by mucosal plasma cells (2) . In our mice, in contrast, the hybridoma tumors resulted in abnormally high levels of circulating IgA. Thus, IgA-mediated protection could have occurred on the mucosal surface, within mucosal tissue, or during a later, systemic stage of infection. Since i.p. injection of S. typhimurium mimics the bacteremia that follows mucosal invasion after oral infection, we tested whether Sal4 IgA produced by hybridoma tumors can protect mice after i.p. injection of S. typhimuHum.
Mice bearing Sal4 hybridoma tumors were challenged i.p. with either wild-type S. typhimurium MT110 or Agg4 mutant MT114. Even at a low dose of 20 bacteria, S. typhimurium were recovered from the spleens of six of seven mice 3 days after i.p. challenge with either the wild-type or the Agg4 mutant (Fig. 3) . Although the absolute number of organisms recovered from the spleen was somewhat lower in mice infected with the wild type than in mice infected with the Agg4 mutant, the numbers of infected animals were equal.
Sal4 (Fig. 4) . In contrast, the Peyer's patches of all six mice that had low levels of serum Sal4 IgA showed some degree of infection of Peyer's patch mucosa. Moreover, two of six mice in this group also had viable bacteria in their spleens. Our other results suggest that the spleens of all six would have become infected if more time had elapsed before sacrifice.
DISCUSSION
The mucosal immune system is thought to provide an early line of defense against both invasive and noninvasive enteric pathogens. In an effort to define more specifically the role of sIgA in this protection, we have examined the ability of a single monoclonal sIgA to protect mice from oral challenge with the highly invasive bacterial pathogen S. typhimunum. We produced this monoclonal IgA by a procedure that involved oral immunization with live attenuated S. typhimurium and then fusion of Peyer's patch lymphoblasts with myeloma cells. One of the hybridomas so obtained (Sal4) was shown to produce polymeric monoclonal IgA antibodies directed against a surface carbohydrate epitope of S. typhimurium. This monoclonal IgA, when delivered into intestinal secretions of nonimmune mice from subcutaneous tumors, protected them against an oral challenge with S. typhimurium. We showed that specific recognition of the bacteria by the IgA was required for this protection by isolating a fully virulent mutant of S. typhimurium that does not produce the epitope and demonstrating that this mutant could infect Sal4 tumor-bearing mice.
The (25) . Thus, S. typhimurium coated with IgA in the lumen could still have been subject to M-cell uptake, but because of the presence of the IgA, may have somehow been prevented from further systemic spread. If so, then organisms should have been consistently recovered from Peyer's patch tissue after oral challenge. However, we observed that three of four mice producing protective levels of Sal4 IgA had sterile Peyer's patches (Fig. 4) , indicating either that mucosal entry had not occurred or that Sal4 IgA was able to "arm" mucosal cytotoxic T cells and promote efficient lysis of any organisms that succeeded in entering the mucosa (18, 22 (22) . These possibilities warrant further study with these and other monoclonal antibodies.
If sIgA protects simply by agglutinating live organisms in the intestinal lumen, protection could theoretically be accomplished by sIgA against any abundant surface component. In related studies, we have shown that secretion of monoclonal IgA antibodies directed against abundant microbial surface components protected against mucosal invasion by reovirus (24) and against diarrheal disease caused by V. cholerae (26) . Moreover, the surface component does not need to be a virulence factor. This was demonstrated in the present study by the existence of a fully virulent S. typhimurium mutant that lacks the protective epitope.
The results presented in this paper indicate that specific sIgA alone, if directed against the bacterial surface and secreted in sufficient amounts, can protect against mucosal invasion and systemic disease caused by S. typhimurium. It follows that individuals who are orally vaccinated with recombinant antigens delivered in live Salmonella vectors might secrete sufficient amounts of anti-Salmonella IgA to prevent subsequent mucosal immunizations with this vector. In our studies, however, sIgA-mediated protection could be overcome by very high oral doses of virulent organisms. Thus, our analysis of the role of sIgA in immunity to Salmonella sp. is relevant not only to understanding what constitutes effective mucosal immune protection against invasive Salmonella sp. but also to the development of effective Salmonella vectors as vaccines.
